1,725,342 research outputs found
IFNγ and IL2 ELISpot responses in GS-4774-immunized mice.
No full text<p>(A) LN cells from 5 pooled GS-4774- or 5 pooled Yvec-immunized BALB/c mice were stimulated with a 1∶1 mixture of <i>E. coli</i> or <i>Pichia pastoris</i> yeast-expressed HBsAg and HBcAg (cS&C, and yS&C, 3 µg/mL each). Control “no stim” wells contained growth medium plus 10% FBS only. Left, IFNγ; right, IL2. <b><u>P values</u></b>, GS-4774 vs. Yvec: cS&C-IFNγ, 0.0001; yS&C-IFNγ, 0.001; cS&C-IL2, 0.004; yS&C-IL2, 0.027. (B) IFNγ ELISpot response in GS-4774-or Yvec-immunized C57BL/6 mice. LN cells of 5 immunized mice per group were pooled and stimulated as in (A). <b><u>P values</u></b>, GS-4774 vs. Yvec: cS&C, 0.020; yS&C, 0.0081. (C) IFNγ ELISpot responses specific for acute-resolved, MHC class I restricted epitopes in GS-4774- or Yvec-immunized HLA-A*02∶01 tg mice (n = 5 mice per group). HBcAg 11–27: ATVELLSFLPSDFFPSV; HBsAg 14–22: VLQAGFFLL; yS&C and no stim, see panel A. (D) IL2 ELISpot responses to novel HBxAg epitopes in BALB/c mice. Splenocytes from 10 immunized mice were pooled and stimulated with 7 µM of 44 different 9-mer and 32 different 15-mer peptides for 4 days followed by a 24 h IL2 ELISpot assay. Only positive responding peptides are shown here (see also <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0101904#pone.0101904.s002" target="_blank">Fig. S2</a> for full results) and are defined as those with > 40 spots per million splenocytes in GS-4774 immunized mice and for which the GS-4774/Yvec response ratio was >2.5. Sequences of positive responding peptides: VLHKRTLGL, AHQFLPKVLHKRTLG or HKRTLGLSAMSTTDL. <b><u>P values</u></b>, GS-4774 vs. Yvec: VLHKRTLGL, 0.005; AHQFLPKVLHKRTLG, 0.061; HKRTLGLSAMSTTDL, 0.034. Error bars: s.e. for replicate stimulations of the pooled immune cells.</p
Block Card 4774 Violet Road
No full textThis image was produced by the Auditor's Office in Lucas County, Ohio for tax assessment purposes. Associated dates are approximate. Descriptive terms related to this photograph include: Cape Cod Style | 4774 Violet Street (Toledo, Ohio) | Dwelling | Harvest Lane Home Sites (Toledo, Ohio) | Franklin Park Area (Toledo, Ohio) | Trilby Area (Toledo, Ohio)
Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study
No full textAbstractBackgroundGS-4774 is a recombinant, heat-killed, yeast-based immunotherapy engineered to express hepatitis B virus (HBV)-specific antigens. GS-4774 is being developed as a therapeutic vaccine for chronic HBV infection. The aim of this study was to assess the safety, tolerability and immunogenicity of GS-4774 in healthy subjects.DesignThis was a randomized, open-label, dose-ascending study. Subjects were allocated to one of three dose groups (n=20 per group) to receive 10, 40 or 80 yeast units (YU; 1YU=107 yeast) of GS-4774 in two immunization regimens (five subcutaneous injections at weekly intervals with one monthly booster or three subcutaneous injections at monthly intervals). T-cell-mediated responses were determined by interferon (IFN)-γ enzyme-linked immunospot (ELISpot) assay and lymphocyte-proliferation assay (LPA).ResultsAdverse events were reported by 39 of 60 (65%) subjects; all were mild or moderate and none was serious. Adverse events occurred most frequently in the highest dose group, 80YU, and the number of individual events was higher after weekly immunization than monthly. The most common adverse events were injection-site reactions. Most (88%) subjects responded to GS-4774 by at least one of the T-cell assays. Following immunization with GS-4774, IFN-γ-producing T-cells specific for HBV antigens were detectable in 30 (51%) subjects. The ELISpot response was observed at all doses, with the highest frequency of responders occurring at the highest dose (10YU: 45%; 40YU: 35%; 80YU: 74%). Proliferative responses to HBV recombinant antigens were observed in 90% subjects; responses were mainly independent of GS-4774 dose and immunization regimen.ConclusionsGS-4774 was safe and well-tolerated in healthy subjects with injection-site reactions being the most frequently reported adverse events. With both weekly and monthly regimens, GS-4774 provided HBV-specific immune responses at all doses evaluated. Further evaluation of GS-4774 is ongoing in patients with chronic HBV infection.Clinical trial registry: Clinicaltrials.gov (NCT01779505
4774. Gilg (Aegidius) Tschudi, Chronicon Helveticum
No full text4774. Gilg (Aegidius) Tschudi, Chronicon Helveticum. In: Molinier Auguste. Les Sources de l'histoire de France - Des origines aux guerres d'Italie (1494). V. Introduction générale - Les Valois (suite), Louis XI et Charles VIII (1461-1494) Paris : A. Picard et fils, 1904. p. 53
Linked collectors and determiners for: New species and findings of Pagastia Oliver (Diptera: Chironomidae: Diamesinae) from Central Asia, with DNA barcoding of known species of the genus.
No full textNatural history specimen data linked to collectors and determiners held within, "New species and findings of Pagastia Oliver (Diptera: Chironomidae: Diamesinae) from Central Asia, with DNA barcoding of known species of the genus". Claims or attributions were made on Bionomia by volunteer Scribes, <a href="http://bionomia.net/dataset/a2120d24-68fa-4774-acda-400fbcb0e9e8">https://bionomia.net/dataset/a2120d24-68fa-4774-acda-400fbcb0e9e8</a> using specimen data from the dataset aggregated by the Global Biodiversity Information Facility, <a href="https://gbif.org/dataset/a2120d24-68fa-4774-acda-400fbcb0e9e8">https://gbif.org/dataset/a2120d24-68fa-4774-acda-400fbcb0e9e8</a>. Formatted as a Frictionless Data package
Is somatostatin receptor scintigraphy suited to detection of acute infectious disease?
Get PDFContains fulltext :
4774.pdf (Publisher’s version ) (Open Access
Linked collectors and determiners for: Vascular Plants, Museum of Archaeology, University of Stavanger.
No full textNatural history specimen data linked to collectors and determiners held within, "Vascular Plants, Museum of Archaeology, University of Stavanger". Claims or attributions were made on Bionomia by volunteer Scribes, <a href="http://bionomia.net/dataset/b4926f5d-6426-4774-83fa-099e927862a1">https://bionomia.net/dataset/b4926f5d-6426-4774-83fa-099e927862a1</a> using specimen data from the dataset aggregated by the Global Biodiversity Information Facility, <a href="https://gbif.org/dataset/b4926f5d-6426-4774-83fa-099e927862a1">https://gbif.org/dataset/b4926f5d-6426-4774-83fa-099e927862a1</a>. Formatted as a Frictionless Data package
Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B
No full textGS-4774 is a heat-inactivated, yeast-based, T-cell vaccine designed to elicit hepatitis B virus (HBV)-specific T-cell responses. We evaluated the safety, tolerability and efficacy of GS-4774 in patients with chronic HBV infection
Cross-presentation of HBV antigens to T cells by GS-4774-pulsed human DCs.
No full text<p>Tarmogen (GS-4774 or Yvec)-pulsed DCs (TPDCs) were incubated in an IFNγ ELISpot plate with HBs183–91 or HBc18–27 TCR re-directed CD8<sup>+</sup> T cells at a 2∶1 effector:target ratio (10,000 T cells:5000 moDC). <b><u>P- values</u></b>, GS-4774 vs. Yvec: HBc18–27, 0.048; HBs183–91: 0.08. The experiment was conducted twice and similar results were obtained each time.</p
- …
